Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats

Lipids Health Dis. 2011 Sep 21:10:165. doi: 10.1186/1476-511X-10-165.

Abstract

Background: This study was an investigation of the effects of ingesting a daily dose of isolated glycinin soy protein (11S globulin), in association with rosuvastatin, on the control of hypercholesterolemia in experimental animals.

Methods: Male Wistar rats were kept in individual cages under appropriate controlled conditions of temperature, light and humidity. The animals were divided into five groups (n = 9): 1) standard (STD): fed on casein as protein source; 2) hypercholesterolemic (HC): STD plus 1% cholesterol and 0.5% cholic acid; 3) HC+11S: hypercholesterolemic + glycinin (300 mg/kg/day); 4) HC+ROS: hypercholesterolemic + rosuvastatin (10 mg/kg/day); 5) HC+11S+ROS: HC diet, the 11S protein and the drug in the doses given in (3) and (4). The protein and the drug were administered by gavage for 28 days. The results indicated that the addition of 1% cholesterol and 0.5% cholic acid induced hypercholesterolemia in the animals without interfering with their weight gain.

Results: A single daily dose of glycinin contributed an additional 2.8% of dietary protein intake and demonstrated its functional role, particularly in raising HDL-C, decreasing triglycerides in the liver and improving the atherogenic index in animals exposed to a hypercholesterolemic diet.

Conclusion: Most of the beneficial effects of the isolated treatments disappeared when the drug (rosuvastatin) and the protein (glycinin) were taken simultaneously. The association was shown not to interact additively, as noted in the plasma levels of total cholesterol and non-HDL cholesterol, and in the significant increase of cholesterol in the liver. Studies are in progress to identify the effects of peptides derived from the 11S globulin and their role in cholesterol metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis / prevention & control
  • Cholesterol / blood
  • Cholesterol / metabolism
  • Cholesterol, Dietary / adverse effects
  • Cholesterol, HDL / blood*
  • Cholic Acid / adverse effects
  • Combined Modality Therapy
  • Dietary Supplements*
  • Fluorobenzenes / antagonists & inhibitors*
  • Fluorobenzenes / therapeutic use
  • Food-Drug Interactions*
  • Globulins / isolation & purification
  • Globulins / therapeutic use*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / diet therapy*
  • Hypercholesterolemia / drug therapy
  • Hypercholesterolemia / metabolism
  • Lipoproteins / metabolism
  • Liver / metabolism
  • Male
  • Pyrimidines / antagonists & inhibitors*
  • Pyrimidines / therapeutic use
  • Rats
  • Rats, Wistar
  • Risk Factors
  • Rosuvastatin Calcium
  • Soybean Proteins / isolation & purification
  • Soybean Proteins / therapeutic use*
  • Sulfonamides / antagonists & inhibitors*
  • Sulfonamides / therapeutic use
  • Triglycerides / metabolism

Substances

  • Cholesterol, Dietary
  • Cholesterol, HDL
  • Fluorobenzenes
  • Globulins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins
  • Pyrimidines
  • Soybean Proteins
  • Sulfonamides
  • Triglycerides
  • lipoprotein cholesterol
  • Rosuvastatin Calcium
  • glycinin
  • Cholesterol
  • Cholic Acid